^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    JIN-A02

    i
    Other names: JIN-A02
    Company:
    J Ints Bio
    Drug class:
    EGFR inhibitor
    Related drugs:
    9ms
    A Phase 1, 2 Study to Evaluate the Safety and Anti-tumor Activity of JIN-A02 in Patients with EGFR Mutant Advanced NSCLC (IASLC-WCLC 2023)
    JIN-A02, a 4th generation EGFR TKI, selectively and reversibly binds to EGFR mutations, including C797S mutation that causes resistance to Osimertinib. Primary end points include dose limiting toxicity and AE/SAE for part A, RP2D for part B, and objective response rate for part C. Part A of JIN-A02 study has begun site activation in January 2023 in US, approved in Korea and is awaiting regulatory approval in Thailand. Clinical trial information: NCT05394831
    Clinical • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR C797S • EGFR positive
    |
    Tagrisso (osimertinib) • JIN-A02
    1year
    A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC (clinicaltrials.gov)
    P1/2, N=150, Recruiting, J Ints Bio | Not yet recruiting --> Recruiting | N=95 --> 150 | Trial completion date: Dec 2024 --> Nov 2025 | Trial primary completion date: Dec 2023 --> Jul 2024
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR C797S • EGFR positive
    |
    JIN-A02
    almost2years
    A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC (clinicaltrials.gov)
    P1/2, N=95, Not yet recruiting, J Ints Bio
    New P1/2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR T790M
    |
    JIN-A02